Pay with Crypto and get 10% off your order!
This assay is used to detect and semi quantitatively measure the presence of FDP in plasma.
Fibrinolysis is the enzymatic breakdown of fibrin in blood clots. Plasmin cuts the fibrin mesh at various places, leading to the production of circulating fragments that are cleared by other proteases. Primary fibrinolysis is a normal body process. The fibrinolytic system serves to limit the formation of thrombi and to facilitate healing or recanalization of a vessel with a thrombotic occlusion. Secondary fibrinolysis is the breakdown of clots due to medicine, disorder, or other cause.
Under normal conditions, the fibrinolytic process is localized on the fibrin clots because alpha2-antiplasmin and the plasminogen activator inhibitors prevent fibrinolysis from spreading. Fibrin Degradation Products (FDP) that occur are very heterogeneous and include products derived from fibrin, soluble complexes, degradation products from fibrinogen, and from nonstabilized fibrin. The presence FDP of in plasma can provide important information for the diagnosis of hemostatic disorders. An abnormal fibrinolytic and/or fibrinogenolytic activity shown by high levels of FDP in plasma can be found in clinical states, such as eclampsia, carcinoma (promyelocytic leukemia), cardiac and renal disorders, hepatic disorders, fibrinolysis, pulmonary embolism, deep vein thrombosis (DVT), following surgery or trauma, and after lytic therapy.
Increased FDPs are seen in primary fibrinolysis as well as during fibrin clot breakdown. Elevated FDP levels are a hallmark finding in disseminated intravascular coagulation (DIC). Elevated FDP levels are not specific for DIC and increased FDP levels are often seen in primary fibrinolysis, severe liver disease, including alcoholic cirrhosis, eclampsia, during acute thrombotic episodes.
1. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997; 107(1):105-110. PubMed 8980376
2. Reneke J, Etzell J, Leslie S, et al. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998; 109(6):754-757. PubMed 9620035
3. National Committee for Clinical Laboratory Standardization. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline. 5th ed. Villanova, Pa: NCCLS; 2008. Document H21-A5:28(5).
4. Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol. 1997; 107(6):681-683. PubMed 9169665
5. McGlasson DL, More L, Best HA, et al. Drawing specimens for coagulation testing: Is a second tube necessary? Clin Lab Sci. 1999; 12(3):137-139. PubMed 10539100
6. FDP-Plasma test kit [package insert]. Diagnostica Stago: January 2015 Revision.
Moresco RN, Júnior RH, Cláudio Rosa Vargas L, Mariano da Rocha Silla L. Association between plasma levels of D-dimer and fibrinogen/fibrin degradation products (FDP) for exclusion of thromboembolic disorders. J Thromb Thrombolysis. 2006 Apr;21(2):199-202. PubMed 16622618
Moresco RN, Vargas LC, Voegeli CF, Santos RC. D-dimer and its relationship to fibrinogen/fibrin degradation products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems. J Clin Lab Anal. 2003;17(3):77-79. PubMed 12696076
Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol. 1989 Jan;71(1):65-70. PubMed 2917130
Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost. 2008 Feb;34(1):33-38. PubMed 18393141
